“Semax” and “N-acetyl Semax” are listed side by side across the research-peptide market, and the two-word difference in the name hides a real chemical distinction. Semax is a synthetic heptapeptide built on a fragment of a natural hormone. N-acetyl Semax is the same heptapeptide carrying a small chemical modification at one end — and the form we stock carries a second modification at the other end. This article walks through what Semax is at the sequence level, what N-terminal acetylation and C-terminal amidation change about the molecule, and what the published literature has actually measured.
What Semax is: a synthetic ACTH(4–7) analog with a Pro-Gly-Pro tail
Semax is a synthetic heptapeptide — a chain of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Its structure is best understood as two parts joined together. The first four residues, Met-Glu-His-Phe, correspond to ACTH(4–7) — positions 4 through 7 of adrenocorticotropic hormone, which is also the N-terminal segment of the well-studied ACTH(4–10) neuropeptide region. To that fragment Semax appends a Pro-Gly-Pro tail at the C-terminus.
That construction is reflected in the public chemistry record. In PubChem, the compound is catalogued under the descriptive name “ACTH (4-7), Pro-Gly-Pro-” with the molecular formula C₃₇H₅₁N₉O₁₀S (CAS 80714-61-0), which directly encodes the ACTH(4–7)-plus-Pro-Gly-Pro design. The Pro-Gly-Pro tail is not cosmetic: it is a deliberate stabilizing element, because proline-containing termini resist many of the exopeptidases that would otherwise trim a short peptide from its ends. So at baseline, Semax is already an engineered analog, not a raw hormone fragment.
What N-terminal acetylation changes at the molecular level
The defining structural difference between plain Semax and N-acetyl Semax is a single chemical group: an acetyl group (CH₃CO–) attached to the free N-terminus of the peptide — the α-amino group of the leading methionine residue. This is a small change in mass but a meaningful one in chemistry.
Acetylation matters because the N-terminus is a primary point of enzymatic attack. Aminopeptidases recognize a free α-amino group and cleave residues off the front of a peptide one at a time. Capping that amino group with an acetyl moiety removes the free amine these enzymes recognize — the standard rationale for N-terminal acetylation as a stability modification. In effect:
- Plain Semax — free N-terminus; the leading methionine is exposed to aminopeptidase recognition.
- N-acetyl Semax — the N-terminus is blocked by an acetyl cap, removing the free amine that front-end exopeptidases target.
That front-end vulnerability is grounded in degradation studies of Semax itself. In a serum-enzyme study, the breakdown of Semax and of ACTH/MSH(4–10) was dissected using selective peptidase inhibitors, and aminopeptidase activity was identified as a substantial contributor to degradation, with inhibitors such as bestatin and puromycin reducing a notable share of the degrading activity (Potaman et al., Peptides, 1993). Capping the residue those enzymes attack is the molecular logic behind acetylating Semax.
What amidation adds — and why our product is the amidate form
It is important to be precise about exactly which molecule we stock. Our product is N-Acetyl Semax Amidate — not plain Semax, and not only the N-acetylated form. It carries two end modifications relative to the parent heptapeptide:
- N-terminal acetylation — an acetyl cap on the leading methionine, as described above.
- C-terminal amidation — the free carboxylic acid (–COOH) at the tail end is converted to a carboxamide (–CONH₂).
Where acetylation blocks front-end (aminopeptidase) cleavage, C-terminal amidation removes the free carboxyl group that carboxypeptidases recognize at the other end. The result is a molecule that differs from plain Semax at both ends: an acetyl group at the head and an amide at the tail. This is why “Semax vs N-acetyl Semax” is not a comparison of one molecule against a slightly tweaked copy — for our amidate product it is the reference heptapeptide versus a doubly end-capped analog of it.
What published studies on Semax actually measured
The body of published research was generated largely on plain Semax, so it is the reference point, not a record of our amidate form. Two strands of that work are relevant here: degradation/stability and downstream molecular signaling.
On degradation, beyond the serum-enzyme inhibitor study above (Potaman et al., 1993), a later study characterized the binding of Semax to plasma membranes of the rat forebrain basal nuclei and tracked its biodegradation there (Dolotov et al., Russian Journal of Bioorganic Chemistry, 2004). Together these establish which enzymes act on the molecule and where — the mechanistic basis for why end-capping modifications like acetylation and amidation are used.
On molecular signaling, research has measured changes in neurotrophin systems in rodent models. One study reported that a single administration of Semax was associated with increased BDNF protein and trkB expression in the rat hippocampus (Dolotov et al., Brain Res, 2006). A later study used real-time PCR to compare the time course of NGF and BDNF gene expression across rat hippocampus, frontal cortex, and retina under Semax action, reporting region-specific changes in those transcripts (Shadrina et al., J Mol Neurosci, 2010).
Two cautions are worth stating plainly. First, these are measurements in specific laboratory animal models, not statements about any effect in a person. Second, this literature was conducted predominantly on plain Semax; it does not directly characterize the N-acetyl amidate form, whose end caps are expected on chemical grounds to alter the molecule’s susceptibility to the enzymes those degradation studies identified.
How it compares to a related ACTH/peptide-analog reference
Semax is often discussed alongside Selank, another synthetic Russian-developed peptide built by attaching a stabilizing tail to a parent sequence. Selank is an analog of the immunomodulatory peptide tuftsin extended with a C-terminal Pro-Gly-Pro tripeptide — the same Pro-Gly-Pro stabilizing strategy seen in Semax. The shared motif illustrates a principle in this class: short peptides are chemically fragile at their termini, and the recurring engineering answer is to modify the ends — whether by adding a proline-rich tail or, as with N-acetyl Semax amidate, by capping both the N- and C-termini outright.
Frequently asked questions
What is the difference between Semax and N-acetyl Semax?
Plain Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro with free termini. N-acetyl Semax carries an acetyl group capping its N-terminus. The form we stock, N-Acetyl Semax Amidate, adds a second modification — C-terminal amidation — so it is capped at both ends relative to plain Semax.
What is Semax derived from?
Semax is a synthetic analog of an ACTH fragment. Its first four residues (Met-Glu-His-Phe) correspond to ACTH(4–7), the N-terminal part of the studied ACTH(4–10) region, and a Pro-Gly-Pro tail is attached at the C-terminus. PubChem catalogues the compound under the descriptive name “ACTH (4-7), Pro-Gly-Pro-.”
Why is Semax acetylated?
The N-terminus of a peptide is a primary target for aminopeptidases, which cleave residues from the free amino end. Degradation studies of Semax identified aminopeptidase activity as a substantial contributor to its breakdown (Potaman et al., 1993). Capping the N-terminus with an acetyl group removes the free amine those enzymes recognize, which is the standard chemical rationale for N-terminal acetylation.
What does C-terminal amidation change?
Amidation converts the free carboxylic acid at the peptide’s tail into a carboxamide, removing the free carboxyl group that carboxypeptidases recognize. Where acetylation protects the front end, amidation protects the back end, so the doubly modified molecule is capped at both termini.
Is our product plain Semax?
No. Our listed product is N-Acetyl Semax Amidate — the N-terminally acetylated and C-terminally amidated form. Plain “Semax” is used in this article only as the structural and research reference point for the comparison.
What have studies on Semax measured?
Published research on plain Semax has characterized which serum and tissue enzymes degrade it (Potaman et al., 1993; Dolotov et al., 2004) and measured changes in neurotrophin systems — increased BDNF and trkB expression in the rat hippocampus (Dolotov et al., 2006) and region-specific NGF/BDNF gene-expression dynamics (Shadrina et al., 2010) — in rodent models. These measurements are in laboratory animal models and were conducted on plain Semax, not the amidate form.
References
- Potaman VN, et al. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study. Peptides. 1993. PMID: 8392718.
- Dolotov OV, et al. The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Russian Journal of Bioorganic Chemistry. 2004. PMID: 15344653.
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. PMID: 16996037.
- Shadrina M, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience. 2010. PMID: 19662538.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
